Harrow (HROW) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Harrow (HROW) over the past year, gaining 146.7% versus a loss of 26.9%. Over five years, HROW leads with a +209.6% price change compared with -72.5% for IRWD. Harrow is the larger company by market cap ($1.14 billion vs $639.5 million), about 1.8 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.6x vs 11.0x for Harrow).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HROW | IRWD |
|---|---|---|
| Share price | $30.52 | $3.87 |
| Market cap | $1.14B | $639.48M |
| 1-day change | -0.33% | +3.20% |
| YTD return | -37.51% | +11.28% |
| 1-year return | -26.92% | +146.71% |
| 5-year return | +209.61% | -72.55% |
| P/E ratio (TTM) | — | 5.03 |
| Forward P/E | 11.01 | 2.58 |
| EPS (TTM) | $-0.99 | $0.77 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.85 | $5.78 |
| 52-week low | $28.54 | $1.41 |
| Distance from 52-week high | -44.36% | -33.04% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +112.98% | +57.62% |
| Average volume | 555.14K | 2.03M |
| Shares outstanding | 37.49M | 165.24M |
| Employees | 373 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed HROW by 173.6 percentage points over the past year.
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
HROW vs IRWD FAQ
Which is bigger, Harrow or Ironwood Pharmaceuticals?
Harrow (HROW) is larger, with a market capitalization of $1.14B compared with $639.48M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, HROW or IRWD?
IRWD returned +146.71% over the past 12 months, compared with -26.92% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Harrow and Ironwood Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.